CLINICAL_TRIALS
trial_result
· 2021-01-05
Clinical Trial Update: A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma [Phase 1]
Summary
Phase 1 tissue collection study of pembrolizumab (MK-3475) in subjects with resectable advanced melanoma has completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2021-01-05